The aim of this clinical trial is to assess the effects of daily consumption of soy protein
foods on body composition, general health status and dietary intake outcomes in generally
1. Subject is male or female, 8-11 years of age, inclusive.
2. Subject is judged to be in good health on the basis of medical history.
3. Subject is a regular consumer (5 out of 7 d) of breakfast and snacks.
4. Subject has a BMI-for-age within the 75th and 95th percentile (Appendix 3).
5. Subject is willing to follow dietary changes consistent with the Dietary Guidelines
for Americans 2010 throughout the study period (Appendix 5).
6. Subject/guardian understands the study procedures and signs forms providing
assent/informed consent to participate in the study and authorization for release of
relevant protected health information to the study Investigators.
1. Subject has a diagnosis of attention deficit disorder, with or without hyperactivity.
2. Subject requires special educational services related to cognitive or attentional
disorders, neurologic diseases, and physical disabilities.
3. Subject is a girl who has begun menses.
4. Subject is at Tanner Stage IV or higher, as described by parent/guardian per
self-assessment questionnaire (Appendix 2).
5. Subject has a history or presence of a clinically relevant cardiac, renal, hepatic,
endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal,
pancreatic, or neurologic disorder.
6. Subject has a known allergy or sensitivity to the study foods.
7. Use of sleep aids within 2 weeks of visit 1 (week -1) and throughout the study.
8. Subject has extreme dietary habits, in the judgment of the Investigator.
9. Subject has used any weight loss supplements, programs, or meal replacement products
(within 2 weeks of visit 1, week -1) intended to alter body weight (Appendix 1).
10. Subject has a history of an eating disorder (e.g., anorexia nervosa, bulimia nervosa
or binge eating) diagnosed by a health professional.
11. Involvement in any clinical trial within 30 d prior to the screening visit.
12. Individual has a condition the Investigator believes would interfere with his or her
ability to provide informed consent, comply with the study protocol, which might
confound the interpretation of the study results or put the person at undue risk.